Head-to-head bispecific vs CAR-T in second-line LBCL
Nobody has directly compared an off-the-shelf bispecific with CAR-T in the same patients; a trial would settle where each belongs.
CAR-T has phase 3 EFS and OS wins in early relapse; bispecifics have single-arm activity and one mixed phase 3 (EPCORE DLBCL-1). Access, cost, and vein-to-vein time favour bispecifics.
Pages like this
not linked directly; found by shared links- TrialSTARGLO
Shares Glofitamab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
- IdeaMandatory public reporting of vein-to-vein time and failure rate per CAR-T product
Shares Axicabtagene ciloleucel, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- TrialEPCORE DLBCL-2
Shares Epcoritamab, Diffuse large B-cell lymphoma.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaFull refund for CAR-T if the patient has not responded at three months
Shares Axicabtagene ciloleucel, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- TrialEPCORE DLBCL-1
Shares Epcoritamab, Diffuse large B-cell lymphoma.
- TermStep-up dosing (T-cell engagers)
Shares Glofitamab, Epcoritamab, T-cell engagers (bispecific).